Hiroyuki Nagase

16PUBLICATIONS
51CO-AUTHORS
Ngā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)Human impacts of climate change and human adaptationAllergyPharmacogenomicsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 24, 2026
Reply to Siddiqui et al., Godbout et al., and to Chang and Mao.

|Jun 01, 2026
Risk Factors for COVID-19 mRNA Vaccine-Associated Exacerbations in Patients With Obstructive Airway Diseases: REsearch for Asthma and COPD ExacerbaTION Caused by COVID-19 mRNA Vaccination (REACTION Study).

|May 13, 2026
Effectiveness of FF/UMEC/VI versus ICS/LABA in Patients with Uncontrolled Asthma Treated in Routine Clinical Practice (PERFORM): A Pragmatic Randomized Controlled Trial.

|Mar 23, 2026
Adherence to Biologic Therapies is Associated with Improved Clinical Outcomes and Reduced Healthcare Resource Utilization in Patients with Severe Asthma in Japan.

Hiroyuki Nagase, Urvee Karsanji, Hideaki Kunishige

|Feb 25, 2026
Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE).

Geoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch

|Oct 21, 2025
High Serum Thymic Stromal Lymphopoietin (TSLP) Is Characteristic of Late-Onset, Long-Duration, Eosinophilic Asthma.

Maho Suzukawa, Ken Ohta, Hiroyuki Tashimo

Pageof 3

Frequent Collaborators

3 joint publications

Koichi Fukunaga

3 joint publications

Takeo Ishii

3 joint publications

Shiyuan Zhang

2 joint publications

Geoffrey Chupp